DFU Case Study: 12-Week Healing With Offloading Protocol

DFU Case Study: 12-Week Healing With an Offloading Protocol

Diabetic foot ulcer case studies reveal patterns that textbooks summarize but clinical practice makes vivid. Every DFU has a story: how it started, why it stalled, and what combination of interventions finally moved it toward closure. This composite case follows a hypothetical patient through 12 weeks of treatment, demonstrating how offloading, serial debridement, and skin substitute application work together when each is applied at the right time.

The patient, clinical details, and timeline presented here are entirely composite and hypothetical, created for educational purposes. No real patient data is represented.

Initial Presentation and Assessment

The hypothetical patient is a 62-year-old male with type 2 diabetes (HbA1c 8.2%), peripheral neuropathy confirmed by monofilament testing, and a Wagner Grade 2 ulcer on the plantar surface of the first metatarsal head. The wound measures 2.8 cm x 2.1 cm x 0.3 cm. The wound bed shows approximately 60% granulation tissue and 40% fibrinous slough. Periwound skin is callused with mild maceration at the wound margins. Pedal pulses are palpable but diminished. ABI is 0.92 on the affected limb.

Risk Factor Inventory

The assessment reveals several compounding factors:

Neuropathy. The patient reports no pain at the wound site. He discovered the ulcer after noticing drainage on his sock, a presentation pattern common in neuropathic DFUs.
Biomechanical load. Plantar first metatarsal head location indicates high-pressure repetitive loading during ambulation. Without offloading, every step reinjures the wound bed.
Glycemic control. HbA1c of 8.2% is above the 7.0% target. Elevated glucose impairs neutrophil function and collagen synthesis, slowing wound healing at the cellular level.
Callus formation. Periwound callus concentrates pressure at wound margins, creating a mechanical barrier to epithelial migration.

For a comprehensive overview of DFU classification and clinical pathways, see the Diabetic Foot Ulcer Guide.

Treatment Plan: Three Pillars

The treatment plan rests on three interventions applied simultaneously, not sequentially.

Pillar 1: Offloading

Total contact casting (TCC) is the gold standard for plantar DFU offloading. In this composite case, a removable cast walker (RCW) with an irremovable modification (wrapped with a single layer of cohesive bandage to discourage removal) is selected. The rationale: TCC requires cast changes at every visit, which adds procedure time in a mobile wound care setting where every minute counts. The irremovable RCW achieves comparable pressure redistribution while allowing wound inspection without full cast removal.

The patient is educated that the device must stay on during all weight-bearing activity. Compliance with offloading is the single strongest predictor of plantar DFU healing. Studies consistently show that wounds offloaded with irremovable devices heal at roughly double the rate of those with removable devices, precisely because patients cannot choose to remove them.

For a deeper discussion of offloading modalities and evidence, see Wound Care Offloading Strategies.

Pillar 2: Serial Sharp Debridement

At the initial visit, the fibrinous slough and periwound callus are debrided sharply. The wound bed is converted to 90% granulation tissue post-debridement. Wound dimensions after debridement: 3.0 cm x 2.3 cm x 0.3 cm. The wound is slightly larger after debridement because the true margins were hidden beneath callus. This is expected and documented as such.

Debridement is performed at each subsequent visit as needed. The goal is to maintain a clean granular wound bed free of biofilm and callus so that advanced therapies have a viable surface to work with.

Pillar 3: Skin Substitute Application

At week 4, the wound has reduced to 2.2 cm x 1.7 cm (approximately 35% area reduction). This meets the threshold for continued conservative management, but the treatment team decides to apply a skin substitute to accelerate closure. The rationale: a 50% area reduction at 4 weeks is the benchmark predictor of healing by 12 weeks. At 35%, the wound is healing but at risk of stalling.

A human acellular dermal matrix is applied to the wound bed after debridement. The wound is dressed with a non-adherent contact layer and a moisture-retentive secondary dressing. The offloading device is reapplied.

Weekly Progression: Weeks 1 Through 12

Weeks 1-3: Wound bed converts from mixed slough/granulation to predominantly granular tissue. Periwound callus is debrided at each visit. Wound area decreases from 6.9 cm² to 5.1 cm². The patient is compliant with the irremovable RCW. Glycemic management referral is initiated; endocrinology adjusts medications.

Week 4: Skin substitute applied. Wound area is 3.74 cm². No signs of infection. Periwound skin is healthy with no maceration. HbA1c recheck ordered.

Weeks 5-8: Granulation tissue fills the wound depth. Wound transitions from full-thickness to superficial partial-thickness. Area decreases from 3.74 cm² to 1.6 cm². A second skin substitute application is performed at week 6 to maintain growth factor stimulation. Epithelial migration is visible from wound margins.

Weeks 9-11: Epithelialization accelerates. Wound is now superficial with robust epithelial coverage advancing from all margins. Area decreases from 1.6 cm² to 0.3 cm². Offloading is maintained. The patient asks about discontinuing the boot. He is counseled that premature discontinuation of offloading is the most common cause of DFU recurrence.

Week 12: Wound is fully epithelialized. The wound site is fragile and requires continued protection, but it meets the clinical definition of closure: 100% epithelialization with no drainage.

Post-Closure: Recurrence Prevention

Healing a DFU is not the finish line. Recurrence rates for plantar DFUs range from 40% to 65% within the first year after closure. The post-closure plan includes:

Gradual transition from RCW to therapeutic footwear. The patient is fitted for custom diabetic shoes with accommodative insoles before the RCW is discontinued.
Monthly foot checks. The wound care team continues monthly visits for 3 months post-closure, then transitions to quarterly surveillance.
Patient education. Daily foot inspection, moisture management, and immediate reporting of any skin breakdown.
Glycemic optimization. The endocrinology referral continues. Improved HbA1c (now 7.4%) will reduce recurrence risk.

Documentation Considerations

Every visit is documented with standardized wound measurements (length x width x depth), wound bed composition percentages, periwound assessment, and offloading compliance. Photographs with calibration markers are captured at each visit. This documentation supports medical necessity for debridement codes, skin substitute application codes, and evaluation and management services.

Key Takeaways

Offloading is the intervention with the largest effect size in plantar DFU healing. Irremovable devices outperform removable ones because compliance is engineered rather than requested.
Debridement prepares the wound bed for advanced therapies. Applying a skin substitute to a wound with slough or biofilm wastes the product and delays healing.
The 4-week reassessment rule guides escalation decisions. Less than 50% area reduction at 4 weeks signals the need for advanced intervention or workup for underlying barriers.
Post-closure surveillance is as important as the treatment phase. DFU recurrence rates are high enough that "healed" is the beginning of prevention, not the end of care.
Every visit generates documentation that supports or undermines the billing. Standardized measurements, wound bed percentages, and medical necessity narratives must be captured in real time, not reconstructed later.